We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock

Delisted

PLXP was delisted on the 12th of April, 2023.

33 hedge funds and large institutions have $25.5M invested in PLx Pharma Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0% more funds holding

Funds holding: 3333 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

7% less capital invested

Capital invested by funds: $27.5M → $25.5M (-$2.02M)

Holders
33
Holders Change
Holders Change %
0%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
11
Reduced
11
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
1
Kingdon Capital Management
New York
$9.61M +$75.8K +875 +0.7%
TCP
2
Tourbillon Capital Partners
New York
$2.36M -$1.35M -15,625 -34%
LSVM
3
Lone Star Value Management
Connecticut
$1.8M -$392K -4,518 -17%
6CM
4
683 Capital Management
New York
$1.77M -$115K -1,327 -6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.57M +$137K +1,584 +9%
LOAMU
6
Lombard Odier Asset Management (USA)
New York
$1.51M +$1.65M +19,008 New
GPP
7
Great Point Partners
Connecticut
$871K +$952K +10,989 New
EA
8
Emerald Acquisition
Washington
$854K +$934K +10,776 New
Goldman Sachs
9
Goldman Sachs
New York
$776K -$362K -4,173 -30%
TCM
10
Timpani Capital Management
Wisconsin
$635K +$217K +2,502 +45%
BC
11
Broadfin Capital
New York
$444K -$4.56M -52,650 -90%
FPC
12
Falcon Point Capital
California
$385K +$46.7K +539 +12%
GC
13
Guggenheim Capital
Illinois
$376K -$5.89K -68 -1%
Renaissance Technologies
14
Renaissance Technologies
New York
$355K +$107K +1,237 +38%
Northern Trust
15
Northern Trust
Illinois
$333K +$19.9K +230 +6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$328K
AAP
17
Ardsley Advisory Partners
Connecticut
$322K -$135K -1,562 -28%
RJA
18
Raymond James & Associates
Florida
$312K +$341K +3,929 New
1CM
19
1492 Capital Management
Wisconsin
$304K -$32.2K -371 -9%
BCM
20
Bridgeway Capital Management
Texas
$244K
BFA
21
BlackRock Fund Advisors
California
$155K +$27.8K +321 +20%
Morgan Stanley
22
Morgan Stanley
New York
$53K -$780 -9 -1%
US Bancorp
23
US Bancorp
Minnesota
$40K
Wells Fargo
24
Wells Fargo
California
$33K +$10.8K +125 +43%
FNYS
25
First New York Securities
New York
$22.8K +$3.29K +38 +15%

PLXP Hedge Fund Activity: Q2 2016 in Review

33 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q2 2016, worth a combined $25.5M — down 7.3% from $27.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PLXP positions and 4 closed out — a net gain of 1 holder — while 11 added to existing stakes and 11 trimmed.

The largest buyer was Lombard Odier Asset Management (USA), opening a new position worth an estimated $1.65M. The largest seller was Broadfin Capital, cutting an estimated $4.56M.

  • 33 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $25.5M of PLx Pharma Inc. Common Stock stock for Q2 2016, down 7.3% quarter-over-quarter.
  • 5 funds opened new PLx Pharma Inc. Common Stock positions in Q2 2016 and 4 closed out, a net change of +1 holder.
  • The largest PLx Pharma Inc. Common Stock buyer in Q2 2016 was Lombard Odier Asset Management (USA), an estimated $1.65M added.
  • The largest PLx Pharma Inc. Common Stock seller in Q2 2016 was Broadfin Capital, an estimated $4.56M sold.

Based on aggregated 13F filings for Q2 2016.